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Human African trypanosomiasis (HAT, also called sleeping sickness), a neglected tropical disease endemic to sub-Saharan Af-
rica, is caused by the parasites Trypanosoma brucei gambiense and T. brucei rhodesiense. Current drugs against this disease
have significant limitations, including toxicity, increasing resistance, and/or a complicated parenteral treatment regimen. DB829
is a novel aza-diamidine that demonstrated excellent efficacy in mice infected with T. b. rhodesiense or T. b. brucei parasites.
The current study examined the pharmacokinetics, in vitro and in vivo activity against T. b. gambiense, and time of drug action
of DB829 in comparison to pentamidine. DB829 showed outstanding in vivo efficacy in mice infected with parasites of T. b.
gambiense strains, despite having higher in vitro 50% inhibitory concentrations (IC50s) than against T. b. rhodesiense strain
STIB900. A single dose of DB829 administered intraperitoneally (5 mg/kg of body weight) cured all mice infected with different
T. b. gambiense strains. No cross-resistance was observed between DB829 and pentamidine in T. b. gambiense strains isolated
from melarsoprol-refractory patients. Compared to pentamidine, DB829 showed a greater systemic exposure when adminis-
tered intraperitoneally, partially contributing to its improved efficacy. Isothermal microcalorimetry and in vivo time-to-kill
studies revealed that DB829 is a slower-acting trypanocidal compound than pentamidine. A single dose of DB829 (20 mg/kg)
administered intraperitoneally clears parasites from mouse blood within 2 to 5 days. In summary, DB829 is a promising preclin-
ical candidate for the treatment of first- and second-stage HAT caused by both Trypanosoma brucei subspecies.
Human African trypanosomiasis (HAT), also known as sleep-ing sickness, is a neglected tropical disease threatening the
health of millions of people in the poorest regions of sub-Saharan
Africa (1). HAT is fatal if left untreated. The disease is caused by
two subspecies of the unicellular parasite Trypanosoma brucei, T.
b. gambiense and T. b. rhodesiense, and is transmitted through the
bite of an infected tsetse fly. Two clinical stages are defined. In the
first stage, the parasites reside in the blood and lymph system,
whereas in the second stage, the parasites cross the blood-brain
barrier (BBB) and infect the central nervous system (CNS). The
disease was almost eliminated around 1960, but it reemerged as a
result of political instability and lack of an adequate health care
and control system (2). The most recent epidemic occurred in the
1990s, when the number of estimated cases in 1998 was alarmingly
high, with about 300,000 cases per year (3). Since the turn of the
millennium, the number of infections has declined due to inter-
ventions to control the disease, such as trapping tsetse flies, sur-
veillance, and appropriate treatment of patients (2, 4). The num-
ber of actual cases in 2009 was estimated at 30,000 annually by the
World Health Organization. Control measures have to be main-
tained by all means, otherwise the disease will reemerge, as history
has shown (2, 4).
The availability of effective drugs is crucial for HAT control
and elimination, as chemotherapy is the only option for cure.
Vaccines are not available for HAT and are unlikely to be devel-
oped, mainly because of the antigenic variation of the surface gly-
coproteins of the parasites (5–7). There are four drugs available as
monotherapies (two for the first stage and two for the second
stage) to treat the disease, and all require parenteral administra-
tion, which is a significant problem in the remote rural areas of
Africa, where HAT primarily occurs. Moreover, drugs used to
treat second-stage HAT (i.e., melarsoprol and eflornithine) are
unsatisfactory due to severe adverse reactions, increasing treat-
ment failures, and/or complicated treatment schedules requiring
frequent infusion. Hence, new or improved chemotherapies are
needed, especially for second-stage HAT.
One of the compounds used to treat first-stage HAT is the
aromatic diamidine drug pentamidine (Fig. 1). It was discovered
in 1941 and has been used against T. b. gambiense infections for 7
decades. It is still highly efficacious, as shown by the fact that no
increase in treatment failures has been reported (6). The di-
amidine structure of pentamidine seems to be essential for its
antiparasitic activity, which is primarily based on binding to the
parasite DNA (8). The exact mechanism of action, however, is still
unknown. During the last 4 decades, our research has focused on
the identification of novel diamidines with improved efficacy, oral
bioavailability, and BBB penetration. One of the first lead com-
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pounds was furamidine (DB75), which is highly active in vitro as
well as in vivo but has poor oral bioavailability. Its methami-
doxime prodrug, pafuramidine (DB289 maleate), has good oral
bioavailability (9) and good oral efficacy in T. b. rhodesiense-in-
fected mice (10). Pafuramidine was selected by the Consortium
for Parasitic Drug Development (CPDD) in 2000 to enter clinical
trials as the first oral drug to be tested for first-stage HAT. During
a phase III clinical trial, this compound was as effective as pent-
amidine and its safety profile was inconspicuous (11). However,
during a phase I clinical trial for safety with an extended treatment
regimen, reversible hepatotoxicity and delayed-onset renal insuf-
ficiency were observed, which led to the discontinuation of pa-
furamidine development (12).
Further screening of novel diamidines and prodrugs has con-
tinued in order to identify compounds that are safer, offer the
possibility of oral administration, and are in particular active in
the CNS for second-stage HAT (10, 13, 14). The prodrug ap-
proach was originally employed to improve oral absorption by
masking the positive charge of amidine moieties but also had po-
tential to improve drug delivery across the BBB, a prerequisite to
cure patients with second-stage infections. Several diamidine pro-
drugs have been tested in the GVR35 CNS mouse model, in which
DB844 and DB868 administered orally cured CNS infections in
mice (10). DB844 and DB868 have been further tested in the
vervet monkey model of second-stage HAT, and results have been
reported recently (15, 16). DB868 was significantly better toler-
ated in vervet monkeys than was DB844 and could be a promising
oral drug candidate, especially for first-stage disease (17).
The active metabolite of the prodrug DB868 is DB829 (or
CPD-0801 [Fig. 1]). It is a cationic aza-diamidine, potent in vitro
against T. b. rhodesiense STIB900 parasites (50% inhibitory con-
centration [IC50], 20 nM). DB829 is of special interest, because
when administered intraperitoneally it cured mice with second-
stage infections (with T. b. brucei) (10). This indicated that it was
able to cross the BBB. DB829 therefore represents a new class of
cationic diamidines that are CNS active and holds promise for the
direct use of active diamidines to treat second-stage HAT. This
potentially avoids any detrimental effects of the prodrug strategy,
such as variable prodrug activation between different patients,
which would simplify pharmacokinetic predictions and dosage
selection.
The aim of this study was to characterize the pharmacokinetics,
in vitro and in vivo activity against T. b. gambiense, and time of
drug action of the CNS-active diamidine DB829. Since more than
98% of HAT cases are due to T. b. gambiense infections currently
(18), it is imperative to determine the effectiveness of DB829
against T. b. gambiense parasites. Isothermal microcalorimetry
(19) was employed to monitor in vitro parasite killing rate (time of
drug action) of DB829 on a real-time basis. Lastly, the in vivo
parasite clearance time and pharmacokinetics of DB829 in mice
were determined. These results are important factors to be con-
sidered for further development of DB829 and related com-
pounds to treat African sleeping sickness.
MATERIALS AND METHODS
Materials. Pentamidine isethionate was purchased from Sigma-Aldrich
(St. Louis, MO). Synthesis of DB829 (or CPD-0801; hydrochloride salt
form) and deuterium-labeled DB75 (DB75-d8; deuterated phenyl rings;
internal standard) has been previously reported (20, 21). CPD-0801 and
CPD-0802 are both synonyms for DB829. The different codes indicate
their different salt forms. CPD-0801 is the hydrochloride salt form, and
CPD-0802 is the diacetate salt form of DB829. Only the hydrochloride salt
form of DB829 was used in this study.
Animals for pharmacokinetic studies. Protocols for the animal stud-
ies were approved by the Institutional Animal Care and Use Committee of
the University of Kansas. Male Swiss Webster mice (weighing 20 to 25 g)
were purchased from the Charles River Laboratories (O’Fallon, MO).
Mice were housed in a clean room under filtered, pathogen-free air, in a
12-h light/dark cycle, and with food pellets and water available ad libitum.
Pharmacokinetics of DB829 and pentamidine after i.v. and i.p. ad-
ministration in mice. DB829 and pentamidine were first dissolved in
sterile water and further diluted with saline (1:1, vol/vol) to the desired
concentrations. This prevented the precipitation that occurred if the com-
pounds were added directly to saline. The dose level for intravenous (i.v.)
administration was 7.5 mol/kg body weight (approximately 2.3 mg/kg
for DB829 and 2.6 mg/kg for pentamidine), which was well tolerated in a
preliminary overt toxicity study in mice. The dose level for intraperitoneal
(i.p.) administration was 20 mg/kg (approximately 65 mol/kg for DB829
and 59 mol/kg for pentamidine), which was the higher of two doses used
in the following efficacy study and was selected to directly evaluate if
pharmacokinetics played a role in determining in vivo efficacy of the two
compounds. The dose volume was 5 ml/kg. Blood samples were collected
via submandibular bleeding (0.04 ml per bleed) for serial sampling or
cardiac puncture (0.8 ml of blood) for terminal sampling. To accurately
determine the concentration-time curve near and shortly after the time to
maximum concentration of drug in plasma (Tmax) and terminal elimina-
tion half-life (t1/2), the time points for blood sampling included 0.0167,
0.0833 (two additional time points for i.v. administration), 0.25, 0.5, 1, 2,
4, 6, 8, 12, 24, 48, and 72 h following drug administration, and three mice
were used for blood sampling at each time point. Plasma was separated by
centrifugation in lithium heparin-coated Microvet tubes (Sarstedt Inc.,
Newton, NC) or Microtainer tubes (BD Biosciences, Franklin Lakes, NJ).
Plasma samples were stored at 20°C until ultraperformance liquid chro-
matography-tandem mass spectrometry (UPLC-MS/MS) analysis.
Unbound fraction in mouse plasma. The unbound fraction of DB829
and pentamidine in mouse plasma was determined using rapid equilib-
rium dialysis devices (Thermo Scientific Pierce, Rockford, IL) as previ-
ously described (22). Blank mouse plasma was spiked with DB829 or
pentamidine to give a final concentration of 1 M, below which they spent
the majority of time after a single i.v. or i.p. administration of the tested
doses. Spiked plasma (in triplicate) was incubated for 6 h at 37°C to allow
equilibration with a phosphate-buffered saline (100 mM, pH 7.4) and
then analyzed for total and unbound concentrations by UPLC-MS/MS.
UPLC-MS/MS analysis. (i) Sample preparation. Plasma samples (2
l) were mixed with 200 l of 7:1 (vol/vol) methanol-water containing
0.1% trifluoroacetic acid and internal standard (1 nM DB75-d8) and then
vortex mixed for 30 s, followed by centrifugation (2,800  g) to pellet
proteins. The supernatant was transferred to a new tube and dried using a
96-well microplate evaporator (Apricot Designs Inc., Covina, CA) under
N2 at 50°C and reconstituted with 100 l of 15% methanol containing
0.1% trifluoroacetic acid.
(ii) Determination of drug concentration. The reconstituted samples
(5-l injection volume) were analyzed for drug concentration using
a Waters Xevo TQ-S mass spectrometer (Foster City, CA) coupled with a
Waters Acquity UPLC I-Class system. Compounds were separated on a
Waters UPLC BEH C18 column (2.1 by 50 mm, 1.7 m) equilibrated at
FIG 1 Chemical structures of DB829 and pentamidine.
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50°C. UPLC mobile phases consisted of water containing 0.1% formic
acid (A) and methanol containing 0.1% formic acid (B). After a 0.15-min
initial holding period at 5% B, the mobile phase composition started with
5% B and was increased to 60% B over 2.2 min with a flow rate of 0.4
ml/min. Then, the column was washed with 90% B for 0.5 min and was
reequilibrated with 5% B for 1.1 min before the next sample was injected. The
characteristic single-reaction monitoring (SRM) transitions for DB829,
pentamidine, and DB75-d8 were m/z 307.1¡273.1, 341.4¡120.1, and
313.2¡296.3, respectively, under positive electrospray ionization mode.
The calibration curves for DB829 and pentamidine ranged from 0.5 nM to
50 M and 2.5 nM to 50 M, respectively, for plasma samples. The inter-
day coefficient of variation (CV) and accuracy were determined by mea-
suring the same preparation of three standards three times on different
days. At concentrations of 5, 500, and 10,000 nM, the intraday CV and
average accuracy of DB829 quantification were 8.4% and 91%, 9.4% and
104%, and 3.6% and 99%, respectively. The interday CV and average
accuracy of pentamidine quantification were 7.4% and 108% (at 5 nM),
4.7% and 93% (at 500 nM), and 8.1% and 97% at (at 10,000 nM), respec-
tively.
(iii) Pharmacokinetic analysis. The area under the plasma concentra-
tion-time curve (AUC), terminal elimination half-life (t1/2), maximum
concentration of drug in plasma (Cmax), and time to reach Cmax (Tmax)
were calculated using the trapezoidal rule-extrapolation method and non-
compartmental analysis (WinNonlin Version 5.0; Pharsight, Mountain
View, CA).
Antitrypanosomal activity of DB829 and pentamidine in vitro. (i)
Preparation of compounds. Compounds were dissolved in 100% di-
methyl sulfoxide (DMSO) and finally diluted in culture medium prior to
the in vitro assay. The DMSO concentration never exceeded 1% in the in
vitro alamarBlue assays at the highest drug concentration. For microcalo-
rimetry assays, the DMSO concentration was kept at 0.1% in all samples to
avoid any DMSO effect on the membrane permeability of the trypano-
somes. Melarsoprol was diluted in water instead of DMSO. For in vivo
experiments, the compounds were dissolved in DMSO and further di-
luted with distilled water to a final DMSO concentration of 10% prior to
administration to the animals.
(ii) Parasites. The T. b. rhodesiense strain STIB900 is a derivative of
strain STIB704 (23), which was isolated from a patient in Ifakara, Tanza-
nia, in 1982. STIB900 was used for routine in vitro screening and for the
standard acute mouse model, which mimics the first stage of HAT. Strain
STIB799, also known as KETRI 243, is a T. b. rhodesiense strain isolated
from a patient from Busoga in Uganda in 1961 after four treatment fail-
ures with melarsoprol (24).
The T. b. gambiense strains used within this study were STIB930, IT-
MAP141267, 130R, 45R, 349R, DAL898R, K03048, and 40R (Table 1). We
included more isolates from the Democratic Republic of the Congo
(DRC) in our panel of different strains, as most of the T. b. gambiense
infections occur in this central African country (25, 26). The strains la-
beled with an “R” were isolated from patients after a melarsoprol treat-
ment failure. STIB930 (also named STIB754) is a derivative of the strain
TH1/78E(031),which was isolated from a patient in Cote d’Ivoire in 1978
(27). ITMAP141267, was isolated from a patient in DRC in 1960 (28).
Strain 130R was isolated from a patient in DRC in 2005 after two treat-
ment failures with melarsoprol. The first relapse was detected 8 months
after a 3-day melarsoprol treatment, and the second relapse was detected
1 year after a melarsoprol-nifurtimox combination therapy (29). Strain
45R was isolated from a patient in DRC in 2005 after two treatment fail-
ures with melarsoprol. The first relapse was detected 1 year after a 3-day
melarsoprol treatment, and the second relapse was detected 8 months
after a melarsoprol-nifurtimox combination therapy (29). Strain 40R was
also isolated from a patient in DRC in 2005, 6 months after failure of the
10-day melarsoprol treatment (29). The strain 349R was isolated from a
patient in DRC in 2006 after a treatment failure with a 10-day melarsoprol
treatment (29). DAL898R was isolated from a patient in Cote d’Ivoire in
1985 after melarsoprol treatment failure (23). DAL898R was the only
strain that had previously shown an increased IC50 for melarsoprol among
the panel of tested DAL (Daloa in Cote d’Ivoire) isolates (23). Strain
K03048 was isolated from a patient in South Sudan in 2003 (30).
(iii) In vitro growth inhibition assays using T. brucei subspecies.
The 50% inhibitory concentrations were determined using the alamar-
Blue assay as described by Raz et al. (31), with minor modifications. As-
says were carried out at least three times independently, set up on different
days and each time in duplicate. Coefficients of variation of these assays
were less than 50%. Different culture and assay media were used for T. b.
gambiense and for T. b. rhodesiense. For T. b. rhodesiense, the compounds
were tested in minimum essential medium with Earle’s salts, supple-
mented according to the protocol of Baltz et al. (32) with the following
modifications: 0.2 mM 2-mercaptoethanol, 1 mM Na-pyruvate, 0.5 mM
hypoxanthine, and 15% heat-inactivated horse serum. For T. b. gam-
biense, a modified protocol of Hirumi and Hirumi (33) was used: Iscove’s
modified Dulbecco’s medium (IMDM) was supplemented with 0.2 mM
2-mercaptoethanol, 1 mM Na-pyruvate, 0.5 mM hypoxanthine, 0.05 mM
bathocuproindisulfate, 1.5 mM L-cysteine-HCl, 2 mM L-glutamine, and
5% heat-inactivated human serum plus 15% heat-inactivated fetal calf
serum.
Serial drug dilutions were prepared in 96-well microtiter plates, and
each well was inoculated with 2,000 bloodstream forms for the T. b. rho-
desiense isolates and with 2,500 bloodstream forms for the T. b. gambiense
isolates. Drug treatment was carried out for 70 h for T. b. rhodesiense and
68 h for T. b. gambiense. Ten microliters of the viability marker alamar-
Blue (12.5 mg resazurin dissolved in 100 ml phosphate-buffered saline)
was then added to each well, and the plates were incubated for an addi-
tional 2 to 6 h until the signal/background fluorescence ratio was about 10
for T. b. rhodesiense isolates or about 5 for T. b. gambiense isolates. The
plates were read in a SpectraMax Gemini XS microplate fluorescence
scanner (Molecular Devices, Sunnyvale, CA) using an excitation wave-
length of 536 nm and an emission wavelength of 588 nm. The IC50s were
calculated from the sigmoidal inhibition curves using SoftmaxPro soft-
ware.
(iv) Microcalorimetry studies using T. brucei subspecies. In vitro
time of drug action was monitored using isothermal microcalorimetry.
Previous experiments have shown that heat flow data can be used as a
proxy for the number of viable cells (34), defined as trypanosomes still
moving under the microscope. With this method, the time to the onset of
drug action and the time to kill the parasite population can be determined
on a real-time basis (19). The same culture media were used for the T. b.
rhodesiense strain and for the T. b. gambiense strains as for the in vitro
growth inhibition assays. Strain STIB900 was used as a representative for
T. b. rhodesiense and STIB930 (and sometimes ITMAP141267) for T. b.
gambiense.
For experiments with permanent drug exposure, bloodstream try-
panosomes (2 ml at 5  104 organisms/ml per ampoule) were placed in
4-ml ampoules and spiked with DB829 or pentamidine at different con-
centrations with a final DMSO concentration of 0.1% (vol/vol). The
trypanocidal drug melarsoprol was dissolved in water and included as a
nondiamidine control for the first experiments with STIB900. Trypano-
TABLE 1 T. b. gambiense isolates
Trypanosome straina Yr of isolation Origin






DAL898R 1985 Cote d’Ivoire
K03048 2003 South Sudan
a Strains labeled with an “R” were isolated from patients after a relapse with a
melarsoprol treatment.
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some-free negative controls contained only culture medium. After the
ampoules had been inserted into the isothermal microcalorimetry instru-
ment (Thermal Activity Monitor, model 249 TAM III; TA Instruments,
New Castle, DE), heat flow was continuously measured (1 reading/sec-
ond) at 37°C. Each experiment with permanent drug exposure was set up
in triplicate and repeated 3 times.
(v) Inoculum studies. For studies of drug effects on different parasite
densities in the inoculum, the parasite density was reduced to 1  104/ml
bloodstream trypanosomes and supplemented with DB829 or pentami-
dine at the desired concentrations. Inhibition of growth and viability was
compared with the samples containing the standard inoculum of 5 
104/ml bloodstream trypanosomes and the same drug concentrations.
Inoculum experiments with higher parasite densities were omitted, as the
heat flow oscillations, which appear at high initial densities, interfere with
drug action (19).
(vi) Drug washout experiments. For the 24-h exposure experiment,
trypanosomes (T. b. rhodesiense strain STIB900 and T. b. gambiense strain
STIB930) were incubated with DB829 for 24 h at 37°C and then washed
twice at 1,850  g for 10 min to remove the compound. Subsequently, the
washed trypanosomes were resuspended in drug-free culture medium
and transferred to ampoules and inserted into the isothermal microcalo-
rimetry instrument. The drug dilution factor after two washing steps was
estimated to be 1,800-fold. The drug-free control samples (drug free,
washed) were washed identically to the drug-containing samples. Each
24-h exposure experiment was set up in triplicate for each assay and re-
peated 2 times.
(vii) Analysis of microcalorimetry heat flow data. The metabolic heat
production rate in each ampoule was recorded continuously. The electric
signal was calibrated to obtain a reading in watts. To facilitate data han-
dling, the recorded data were resampled to obtain an effective sampling
frequency of 1 data point per 90 s, using the manufacturer’s software
(TAM assistant version v1.2.4.0), and exported to Microsoft Excel. A time
correction was needed for the preparation of the ampoules and the trans-
fer from the bench to the calorimeter prior to equilibration in the calo-
rimeter and the measurement. The correction was achieved by adding 45
min to the time recorded by the microcalorimeter. Resulting data were
plotted as heat flow (in W) over time. Each single curve for heat flow (in
W) over time was analyzed using software R (The R Foundation for Sta-
tistical Computing, Vienna, Austria). Due to metabolic oscillations clearly
visible in the heat flow curves, a cubic spline was applied to smooth the
data prior to parameter determination (i.e., onset of drug action, time to
peak, and time to kill). The time to onset of drug action was determined as
the time at which a divergence between the heat flow rate of the drug-free
controls and the drug-containing specimens could be observed (19). The
time to peak was determined as the time point at which the maximum heat
flow was observed for each sample. The reversal shows the time after
which a decrease of the parasite density is expected. The time to kill the
parasite population was defined as the time point at which the heat pro-
duction was reduced to the level of the sterile medium control (base level).
At this time, the metabolic heat production of the culture was below the
detection limit, suggesting that most of the parasites were inactivated.
Typically, a heat flow of 8 W was recorded at the maximum density of
1  106 to 1.5  106 trypanosomes/ml, and the microcalorimeter had a
detection limit around 100 to 200 nW. The surviving population at the
detection limit was about 1.25% to 2.5% of the maximum density, repre-
senting a density of 4  104 trypanosomes/ml.
Finally, the growth rate () of each culture was calculated using the
data of heat over time (i.e., the integrated heat flow data over time). For
this calculation, the Gompertz growth model (35) was fitted over the
whole curve using software R and the Grofit package (36) as described
previously (37, 38). Although both heat and heat flow data can be used for
the determination of the growth rate, the long thermal equilibration pe-
riod and the metabolic oscillations observed previously (19) can interfere
with the curve-fitting process when using the heat flow data. Therefore, in
our case, the calculated growth rate is more precisely determined when
using the heat data. The growth rates calculated by this approach cannot
be directly compared to the growth rate of exponential phase determined
by a conventional approach, because processes such as lysis or chemical
processes due to the nature of the medium might also contribute to the
overall heat signal. The growth rate calculated based on the heat released
by the metabolic activity in the culture should be considered a proxy for
the conventional growth rate (34).
In vivo assays. (i) Measurement of efficacy and time to kill. Adult
female NMRI mice were obtained from Janvier, France. They weighed
between 20 and 25 g at the beginning of the study and were housed under
standard conditions with food pellets and water ad libitum. All protocols
and procedures used in the current study were reviewed and approved by
the local veterinary authorities of the Canton Basel-Stadt, Switzerland.
(ii) Mouse model to measure drug efficacy against T. b. rhodesiense
STIB900. Experiments were performed as previously reported (10) with
minor modifications. Briefly, 72 h prior to drug administration, female
NMRI mice (n  4 per group) were infected i.p. with 5  103 STIB900
bloodstream forms. Drug administration (i.p.) began on day 3 postinfec-
tion and continued for four consecutive days (for a total of 4 doses) for a
standard treatment regimen. Since a full dose-response curve had been
previously determined for DB829 (10), only an effective dose (4  5
mg/kg i.p.) was tested here for DB829. An additional, higher dose (4  20
mg/kg i.p.) was tested for pentamidine due to its inferior in vivo efficacy.
For single-dose treatment, drug administration took place on day 3 only.
A control group was infected but remained untreated. Since the minimum
curative dose of DB829 was 4  5 to 10 mg/kg i.p. (10), we chose 20 mg/kg
i.p. for the single-dose study, expecting that this dose would give a decent
activity without eliciting any toxicity. An additional, lower dose at 5 mg/kg
was also tested to probe the minimal curative single dose. The same dose
regimen was used for pentamidine. All mice were monitored for para-
sitemia by microscopic examination of tail blood until 60 days after infec-
tion when surviving, and aparasitemic mice were considered cured. Mice
with a parasitemia relapse prior to 60 days were not considered cured, and
the time to parasite relapse was recorded to calculate the mean relapse
time (MRD) in days postinfection.
(iii) Mouse model to measure drug efficacy against T. b. gambiense.
Female NMRI mice (n  4 per group) were immunosuppressed with 200
mg/kg cyclophosphamide (Endoxan; Baxter, Deerfield, IL) 2 days prior to
infection with 105 bloodstream forms with one of the four T. b. gambiense
strains (i.e., ITMAP141267, STIB930, 130R, or 45R) (Table 1). Immuno-
suppression with cyclophosphamide followed once a week until the end of
the experiment. Drug administration (i.p.) began on day 3 postinfection
and continued for four consecutive days (for a total of 4 doses) for a
standard treatment regimen. For single-dose treatment, drug administra-
tion took place on day 3 only. A control group was infected but remained
untreated. The same dose regimens as those for T. b. rhodesiense STIB900
infections were evaluated for acute T. b. gambiense infections. Surviving
and aparasitemic mice at day 90 postinfection were considered cured, and
the time to parasite relapse was recorded to calculate MRD in days postin-
fection.
(iv) In vivo time to kill. Trypanosome infection and immunosuppres-
sion (for T. b. gambiense-infected mice) were carried out as described
above for the efficacy experiments. The parasite load varied between the
different mouse models, which was also observed in the efficacy experi-
ments. The parasitemia was higher in STIB900-infected and STIB930-
infected mice than in ITMAP141267-infected mice due to better adapta-
tion of the parasites in mice. Mice were treated with a single dose of 20
mg/kg i.p. 3 days postinfection, the same dose as that used in the pharma-
cokinetic studies. At this dose, DB829 cured all acute T. b. rhodesiense and
gambiense infections in mice, whereas pentamidine initially cleared para-
sites, but 2/4 mice infected with T. b. rhodesiense STIB900 later relapsed.
The first microscopic parasitemia examination was 24 h after treatment
(as DB829 is a slow-acting compound) and was followed by two exami-
nations per day until all parasites had disappeared. When parasite detec-
tion by microscopy was not sensitive enough to detect any parasites, a
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hematocrit buffy coat examination was performed. The first time point at
which no trypanosomes were detected on the microscopic slide or in the
buffy coat was considered the clearance time (or time to kill) in mice. The
detection limit by buffy coat examination was 102 trypanosomes/ml of
blood. Mice were kept and further observed by tail blood examination
until the end of the experiment to verify whether the administered dose
was curative in the infected mice.
RESULTS
Pharmacokinetics of DB829 and pentamidine after i.p. and i.v.
administration in mice. The mean concentration in plasma over
time profiles of DB829 and pentamidine after a single i.p. or i.v.
dose were determined to compare the systemic exposure and
other pharmacokinetic properties of the two compounds (Fig. 2
and Table 2). The profiles exhibited a biphasic decline with an
initial distribution phase and a terminal elimination phase. About
1 min after i.v. administration at 7.5 mol/kg (or approximately
2.3 mg/kg for DB829 and 2.6 mg/kg for pentamidine), concentra-
tion in plasma reached 36.1 and 14.3 M and then declined to
below 0.1 M within 4 to 8 h for DB829 and 0.5 to 1 h for pent-
amidine. DB829 and pentamidine stayed above their IC50s of 20
and 3 nM (against T. b. rhodesiense strain STIB900) for at least 12
h (60 nM for DB829 and 18 nM for pentamidine at 12 h) before
decreasing slightly below the IC50s by 24 h (19 and 2 nM at 24 h,
respectively). The total body clearance of DB829 was considerably
smaller (by 84%) than that of pentamidine. Both compounds ap-
peared to be extensively tissue bound, as indicated by large vol-
umes of distribution (Table 2). The observed terminal plasma
half-lives were 18.1 h for DB829 and 6.8 h for pentamidine, and
the systemic exposure (as determined by AUC) of DB829 was
6.4-fold greater than that of pentamidine. Furthermore, the un-
bound fraction of DB829 in mouse plasma was 4.8-fold greater
than that of pentamidine (Table 2).
After i.p. administration at 20 mg/kg, DB829 and pentamidine
were absorbed into the systemic circulation. DB829 reached a
Cmax of 31.6 M at 0.5 h and pentamidine a Cmax of 6.7 M at 0.25
h postdosing (Table 2). Although both compounds stayed above
their IC50s against strain STIB900 for the entire 72-h experimental
period and had similar terminal half-lives, DB829 achieved signif-
icantly greater exposure; AUC was 6.2-fold greater and Cmax 4.7-
fold greater than for pentamidine.
In vitro activity of DB829 and pentamidine against different
trypanosome isolates. In vitro activity was originally determined
against bloodstream trypanosomes of T. b. rhodesiense reference
strain STIB900 using the alamarBlue assay and a 72-h drug expo-
sure time (10). As most sleeping sickness cases are due to T. b.
gambiense infections, here we tested DB829 and pentamidine
against a panel of different T. b. gambiense isolates. Among them
were isolates from different regions, older and more recent iso-
lates, and isolates from relapse patients after melarsoprol treat-
ment (Table 1). DB829 was less potent against T. b. gambiense
isolates (IC50 in the range of 69 to 314 nM) than against the T. b.
rhodesiense reference strain STIB900 (IC50, 20 nM) (Table 3 and
Fig. 3), as well as T. b. rhodesiense strain STIB799 (IC50, 27 nM)
(unpublished data) and T. b. brucei strain BS221 (IC50,14 nM)
(10). This indicates a reduced in vitro potency of DB829 against
the T. b. gambiense subspecies. Among the T. b. gambiense isolates,
TABLE 2 Pharmacokinetics of DB829 and pentamidine in uninfected
mice
Route Parameter,a unit DB829 Pentamidine
i.v. Dose, mol/kg (mg/kg) 7.5 (2.3) 7.5 (2.6)
Cmax, M 36.1 14.3
AUClast, mol/liter · h 7.5 1.2
AUC0–, mol/liter · h 7.6 1.2
t1/2, h 18 6.8
CL, liter/h/kg 0.99 6.3
Vz, liter/kg 26 66
MRT, h 7.0 3.7
i.p. Dose, mol/kg (mg/kg) 65 (20) 58 (20)
Cmax, M 31.6 6.66
Tmax, h 0.5 0.25
AUClast, mol/liter · h 72 11
AUC0–, mol/liter · h 74 12
t1/2, h 21 34
fu, P, % 40 	 8.2 8.4 	 1.2
a Abbreviations: Cmax, maximum concentration; Tmax, time to reach Cmax; AUClast,
area under the curve from time zero to the last measurable concentration; AUC0 –,
area under the curve from time zero to infinite time; t½, terminal elimination half-life;
CL, total body clearance; Vz, volume of distribution; MRT, mean residence time; fu, P,
unbound fraction in mouse plasma (mean 	 standard deviation).
FIG 2 Concentration-time profiles of DB829 (circles) and pentamidine (tri-
angles) in plasma following intravenous (A) or intraperitoneal (B) adminis-
tration to uninfected mice. A single dose of DB829 (or pentamidine) was
administered at 7.5 mol/kg i.v. or 20 mg/kg i.p. Symbols and error bars
represent means and standard errors (SEs), respectively, of triplicate determi-
nations.
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there was no clear relationship between melarsoprol treatment
failure (strains marked with “R”) and reduced potency of DB829,
whereas pentamidine appeared to be less active against recently
isolated strains (Table 3 and Fig. 3). For example, DB829 was more
potent against three “R” strains (130R, 349R, and DAL898R) than
the reference melarsoprol-sensitive strain STIB930. Furthermore,
pentamidine exhibited reduced trypanocidal activity (IC50, 40
nM) against strains recently isolated (after the year 2000), i.e.,
40R, 45R, 130R, 349R, and K03048. ITMAP141267 was the oldest
strain (isolated in 1960 in DRC) tested in this study, and it was the
strain most sensitive to DB829 and among those most sensitive to
pentamidine. However, no correlation in reduced trypanocidal
activity among T. b. gambiense strains was observed between
DB829 and pentamidine (Pearson r2  0.14, P  0.37; Fig. 3),
suggesting lack of cross-resistance.
In vivo efficacy in T. b. gambiense-infected mice. To investi-
gate whether potency against T. b. gambiense was lower than
against T. b. rhodesiense in vivo as well as in vitro, we tested DB829
and pentamidine in mice infected with four different T. b. gam-
biense isolates and compared their activities with those obtained in
the T. b. rhodesiense STIB900 mouse model. Both compounds
were more efficacious in mice infected with T. b. gambiense strains
than with T. b. rhodesiense strain STIB900 (Table 3). In contrast to
the trend observed in vitro, DB829 cured T. b. gambiense-infected
mice at lower doses than it cured T. b. rhodesiense STIB900-in-
fected mice. DB829 was curative (3/3 or 4/4 mice) at 1  5 mg/kg
i.p. in the T. b. gambiense-infected mice (ITMAP141267 or
STIB930), whereas the same dose was not sufficient to cure all
(only 2/4) T. b. rhodesiense STIB900-infected mice. Similarly, pen-
tamidine was curative (4/4 mice) at 1  20 mg/kg i.p. in all mice
infected with any of the four T. b. gambiense strains, whereas this
dose cured only 2/4 mice infected with T. b. rhodesiense STIB900.
Both compounds were efficacious in mice infected with T. b. gam-
biense strains associated with melarsoprol treatment failure (i.e.,
130R and 45R; Table 3), suggesting lack of cross-resistance with
melarsoprol in vivo.
Comparison of the two drugs showed that despite being less
potent in vitro, DB829 was more active than pentamidine in vivo.
The lowest curative dose of DB829 in STIB900-infected mice was
4  5 mg/kg i.p. or 1  20 mg/kg i.p., but pentamidine was only
partially curative (2/4 mice) at 4  20 mg/kg i.p. (Table 3). For T.
b. gambiense-infected mice, DB829 was completely curative at all
doses tested, even with a single dose of 5 mg/kg i.p. In contrast, it
took a higher dose of 1  20 mg/kg i.p. for pentamidine to achieve
a complete cure. These in vivo experiments highlight the high in
vivo potency of DB829, especially against T. b. gambiense infec-
tions.
In addition to testing i.p. administration, we also evaluated the
efficacy of DB829 via i.v. or oral (p.o.) administration based on the
observed pharmacokinetics of the compound. The maximum
concentration of DB829 in plasma following an i.v. dose of 7.5
mol/kg (or 2.3 mg/kg) was similar (36.1 versus 31.6 M) to that
after an i.p. dose of 65 mol/kg (or 20 mg/kg) (Table 2). Previous
experiments had demonstrated that DB829 could be absorbed af-
ter oral administration, reaching a Cmax of 83 nM following a
single dose of 100 mol/kg (or 31 mg/kg) (14). Hence, we tested
FIG 3 In vitro activities of DB829 and pentamidine against different T. b.
gambiense strains. Symbols represent the average IC50s of three independent
determinations. The first number in parentheses represents IC50 for pentam-
idine, and the second number is the IC50 for DB829. No significant correlation
between pentamidine and DB829 activities was observed (Pearson r2  0.14;
P  0.37).
TABLE 3 In vitro and in vivo antitrypanosomal activity of DB829 and
pentamidine against different T. brucei strains
Organism and drug
regimen (no. of
















20 	 4 3 	 0.8
1  5 2/4 (53.5) NDd
1  20 4/4 2/4 (22.5)
4  5 4/4 1/4 (23)
4  20 ND 2/4 (28.5)
T. b. gambiense
ITMAP141267
69 	 17 6 	 1.2
1  5 3/3c 3/4c (48)
1  20 4/4 4/4
4  5 4/4 4/4
4  20 ND ND
T. b. gambiense
STIB930
304 	 87 2 	 1.1
1  5 4/4 3/4 (59)
1  20 4/4 4/4
4  5 4/4 4/4
4  20 ND ND
T. b. gambiense
130R
99 	 23 53 	 28
1  5 ND ND
1  20 4/4 4/4
4  5 4/4 2/3 (60)
4  20 ND 4/4
T. b. gambiense 45R 302 	 113 81 	 8
1  5 ND ND
1  20 4/4 4/4
4  5 4/4 3/3
4  20 ND ND
a MRD, mean relapse time in days.
b DB829 also cured 3/4 mice at 4  50 mg/kg administered orally, 4/4 mice at 1  10
mg/kg i.p. or 1  10 mg/kg i.v., and 1/4 mice at 4  5 mg/kg i.v. for STIB900-infected
animals.
c The experiment was terminated on day 60 postinfection, instead of day 90 for other
experiments with T. b. gambiense.
d ND, not done.
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DB829 efficacy in the standard mouse model with T. b. rhodesiense
STIB900 using an i.v. dose of 4  5 mg/kg and an oral dose of 4 
50 mg/kg. DB829 cured 1/4 mice after i.v. administration, so it was
less active than with i.p. administration using the same dose regi-
men (Table 3). However, to our surprise, oral DB829 cured 3/4
mice. This was the first time that a cationic diamidine was shown
to have oral efficacy in this first-stage HAT model.
In addition to being less active, DB829 administered i.v. also
showed a narrower therapeutic window, as signs of acute toxicity
(lethal hypotension) were observed above 20 mg/kg of DB829 in a
single dose. In contrast, i.p. administration was much better tol-
erated up to 50 mg/kg. The slow release by the i.p. route seems to
improve tolerability without any loss of efficacy. Pentamidine ex-
hibited a similar tolerability pattern in relation to the site of ad-
ministration, but in general, DB829 was more efficacious than
pentamidine.
Time of drug action in vitro. (i) Parameters to describe time
of drug action. The time of drug action of DB829 and that of
pentamidine in vitro against T. b. rhodesiense strain STIB900 and
T. b. gambiense strains ITMAP141267 and STIB930 were recorded
and analyzed using isothermal microcalorimetry analysis. We
originally proposed to use three parameters (i.e., onset of drug
action, time to peak, and time to kill) to describe time of drug
action (19). Here, another parameter, the growth rate (), was
added to describe how fast the culture grows (if any growth is
observed) and hence the level of growth rate inhibition, i.e.,
1  (drug/drug free).
(ii) Time of drug action against T. b. rhodesiense strain
STIB900. The onset of drug action on T. b. rhodesiense strain
STIB900 ranged from 5 to 19 h for DB829 and from 4 to 14 h for
pentamidine, depending on effective drug concentrations
(0.5 IC50). The onset of drug action of melarsoprol was more
concentration dependent than that of DB829 and pentamidine
(Table 4). At 200 nM (50 IC50), melarsoprol instantly inhib-
ited parasite growth, resulting in a heat flow curve comparable to
that of trypanosome-free control samples (Fig. 4). The time to
peak did not vary much for DB829 (17 to 32 h) at different con-
centrations (20 to 20,000 nM). For melarsoprol and pentamidine,
the time to peak was considerably shorter, and at the high drug
concentration of 200 nM (50 to 80 IC50) it could not be cal-
culated because of complete or almost-complete inhibition. The
time to kill the parasite population ranged from approximately 3
to 4 days for DB829, showing little variation with drug concentra-
tions (ranging from 20 to 20,000 nM). In contrast, for pentami-
dine the time to kill decreased over 6-fold (89 h versus 14 h) as the
drug concentration increased. Melarsoprol (at 200 nM) killed all
parasites in so short a time that time to kill could not be measured
(Table 4 and Fig. 4). The inhibition of growth rate () by DB829
was dependent on drug concentration up to 2,000 nM and did not
reach more than 72% even at the highest drug concentration
tested (20,000 nM, 1,000 IC50) (Table 4). However, pentam-
idine and melarsoprol nearly completely inhibited parasite
growth at 200 nM. From visual inspection, the overall shapes of
the isothermal curves of DB829 and pentamidine were similar, but
the shape was different for melarsoprol, especially at 20 nM (Fig.
4C), presumably as a result of distinct modes of action for cationic
diamidines and organoarsenicals.
(iii) Time of drug action against T. b. gambiense strains. In
drug-free control cultures, the growth rate of the two T. b. gam-
biense strains was lower than that of the T. b. rhodesiense reference
strain STIB900 at identical starting trypanosome densities (5 
104 trypanosomes/ml) (Fig. 5 and Table 4). The time to peak was
53 to 58 h versus 36 h for STIB900, the growth rate () was 0.024
to 0.018 h1 versus 0.029 h1 for STIB900, and the time to death
by overgrowth was also longer, 139 to 170 h compared to 119 h for
STIB900. In cultures treated with drugs, the onset of drug action,
the time to peak, and the time to kill of DB829 and pentamidine
were generally longer for the two T. b. gambiense strains (except
pentamidine against STIB930) than for the T. b. rhodesiense refer-
ence strain STIB900 (Table 4). In particular, the time to kill the
two T. b. gambiense strains with DB829 ranged from 97 to 124 h
(or 4 to 5 days) at effective concentrations of 20,000 to 200 nM.
This is considerably longer than the standard 72 h observed in the
in vitro growth inhibition assay. The slow trypanocidal action
could be one reason for the greatly increased in vitro IC50s of
DB829 observed in the growth inhibition assays with the T. b.
gambiense strains (Table 3 and Fig. 3). However, pentamidine ap-
peared to be faster acting, with a time to kill of 2 days at 20 nM
or higher concentrations (Table 4).
(iv) Effects of drug washout on parasites. To determine
whether continuous drug exposure for several days is required for
DB829 to kill the trypanosomes, experiments were carried out in
which the drug was washed out after 24 h of drug incubation, and
heat flow was compared with that for parasites exposed to the drug
throughout (permanent) the isothermal microcalorimetry assay.
These measurements were compared for two strains (STIB900
and STIB930). The time to peak of the heat flow over time for the
washed, drug-free samples was delayed by 11 to 22 h compared to
that for the drug-free samples that were not washed (subjected to
permanent exposure) (Fig. 6 and Table 5). As both samples were
set up and run simultaneously, we attribute this delay to the loss of
some trypanosomes during the washing steps. Trypanosomes
were still viable, as seen by heat production right after the 24-h
DB829 exposure at 200 or 2,000 nM, but they died later on when
cultured in the drug-free medium (Fig. 6). The times to kill after
drug washout were longer than with permanent drug exposure
(96 versus 72 h for the T. b. rhodesiense reference strain STIB900 at
200 nM and 130 versus 89 h for T. b. gambiense strain STIB930 at
2,000 nM) (Table 5). A 24-h exposure with DB829 at 200 nM was
finally sufficient to kill the T. b. rhodesiense strain STIB900 and at
2,000 nM to kill the T. b. gambiense strain STIB930. A revival of the
parasite strain STIB930 occurred in a single experiment at 200
nM. These results suggest that the trypanosomes took up lethal
concentrations of DB829 at 200 nM (STIB900) or 2,000 nM
(STIB930) in the first 24 h, and this was sufficient to kill them at a
later time.
(v) Effects of inoculum on time of drug action. Inhibition of
trypanosome growth by DB829 was dependent on the initial par-
asite density (inoculum effect). With an inoculum of 5  104/ml,
the growth rate of T. b. rhodesiense strain STIB900 was inhibited by
15% and 52% with DB829 concentrations of 20 nM and 200 nM,
respectively. Considerably stronger inhibition, 72% with 20 nM
drug and 90% with 200 nM drug, was observed with an initial
inoculum of 1  104/ml (Table 5). However, the two parameters,
onset of action and time to peak of the heat flow curves, remained
similar at different inocula (Table 5 and Fig. 7). We also examined
inoculum effects with T. b. gambiense strain STIB930. At a drug
concentration of 200 nM DB829, parasite growth rate was inhib-
ited by 4% and with 2,000 nM by 52% with an initial inoculum of
5  104/ml. Significantly stronger inhibition was observed (42%
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at 200 nM and 91% at 2,000 nM) when the initial inoculum was
1  104/ml (Table 5). As with STIB900, the other two parameters
of the heat flow curves remained similar at different inocula (Ta-
ble 5 and Fig. 7). The same inoculum effects were also observed for
pentamidine (Table 5 and Fig. 7).
(vi) Time of drug action in vivo. The in vivo time of drug
action of DB829 and that of pentamidine were determined,
following a single i.p. dose of 20 mg/kg to mice infected with T.
b. rhodesiense strain STIB900 or T. b. gambiense strains
ITMAP141267 and STIB930, to compare the time of drug ac-
tion in vitro with that in vivo. For mice infected with T. b.
rhodesiense strain STIB900, the in vivo onset of drug action of
DB829 was less than 24 h, which is in accordance with the in
vitro time of the onset of action (5 to 19 h at DB829 concentra-
tions of 20 to 20,000 nM) (Table 4). The in vivo time to kill
(parasite clearance time) was on average 78 h (i.e., the first
mouse was parasite free 72 h after drug administration and the
last mouse after 80 h) (Table 6). This is in the range of the in
vitro time to kill (58 to 98 h; Table 4) at the different DB829
concentrations (20 to 20,000 nM). The time to kill in mice
infected with T. b. gambiense strain ITMAP141267 was on av-
erage 102 h (96 to 120 h), and in STIB930-infected mice, it was
TABLE 4 Drug action analysis of antitrypanosomal compounds by isothermal microcalorimetry















Drug free 36 (4) 119 (13) 29 (2)
DB829
2c 19 (8)c 35 (4) 115 (10) 28 (1) 5
20 19 (4) 32 (3) 98 (5) 25 (1) 15
200 11 (2) 26 (2) 77 (13) 16 (4) 46
2,000 7 (2) 17 (4) 58 (17) 10 (3) 66
20,000 5 (1) 21 (3) 67 (10) 8 (3) 72
Pentamidine
0.2c 23 (3)c 39 (6) 138 (10) 25 (4) 12
2 14 (4) 31 (3) 89 (14) 19 (4) 34
20 4 9 (2) 25 (2) 1 98
200d 4 NM 14 (0) 1 98
Melarsoprol
2c NMa 40 (5) 135 (14) 27 (2) 3
20 7 (3) 25 (11) 107 (56) 7 (4) 74
200d NM NM NM NM 100
STIB930
Drug free 53 (2) 139 (3) 24 (2)
DB829
20c NM 51 (4) 136 (19) 25 (2) 0
200 26 (7) 52 (2) 124 (4) 23 (1) 2
2,000 17 (7) 41 (5) 99 (11) 16 (3) 33
20,000 10 (2) 41 (2) 97 (8) 14 (2) 43
Pentamidine
0.2c NM 53 (2) 140 (3) 23 (2) 4
2 8 (1) 30 (2) 75 (8) 11 (2) 54
20b 4 12 (1) 22 (2) 1 96
200b 4 NM NM 1 96
ITMAP141267
Drug free 58 (4) 170 (12) 18 (3)
DB829
20c NM 57 (5) 167 (4) 17 (3) 6
200 28 (9) 50 (3) 124 (7) 17 (4) 5
2,000 14 (5) 33 (12) 100 (13) 12 (2) 33
20,000 12 (5) 34 (14) 113 (10) 10 (2) 42
Pentamidine
2c 28 (7) 57 (2) 159 (3) 18 (3) 0
20 6 (1) 10 (1) 41 (8) 3.5 (0.7) 80
200 4 (1) 8 (2) 23 (9) 1.2 (0.4) 94
a NM, not measurable.
b Initial inoculum density was 5  104 trypanosomes/ml.
c Inhibition was too small to accurately recover parameters from every experiment performed.
d Inhibition was too strong to accurately recover parameters from every experiment performed.
e Inhibition is measured by the formula [1  (drug/drugfree)]  100.
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62 h (56 to 80 h) (Table 6). This is similar to or slightly faster
than the in vitro time to kill for these two parasite strains (100
to 124 h and 99 h, respectively, at approximately 10 IC50)
(Table 4).
In addition, the in vivo times to kill of pentamidine were
shorter than those of DB829 in all experiments, although some
mice infected with the T. b. rhodesiense strain STIB900 relapsed
later (Table 3). The in vivo times to kill of pentamidine were on
average 26 h, 30 h, and 48 h for mice infected with T. b. rhodesiense
strain STIB900 and T. b. gambiense strains ITMAP141267 and
STIB930, respectively. These results are similar to the in vitro time
to kill at relevant drug concentrations (around 20 nM) (Table 4).
The parasite load in STIB930-infected mice was higher than in
mice with ITMAP141267 infections due to better adaptation of
STIB930 in mice.
DISCUSSION
Recent efforts to enhance the CNS activity of antiparasitic diami-
dines led to the discovery of aza analogues of furamidine. One of
these, DB829, cured all mice in the second-stage HAT model using
T. b. brucei strain GVR35 when administered intraperitoneally
(10), in spite of the dogma that cationic diamidines cannot tra-
verse cellular membranes via passive diffusion. This liability limits
their oral bioavailability and brain penetration, so that they are
generally considered to be effective only against first-stage HAT
and only through parenteral administration. Our discovery of
FIG 4 Microcalorimetry growth profiles of T. b. rhodesiense strain STIB900 in the presence of various concentrations of DB829 (A), pentamidine (B), and
melarsoprol (C). The drug-free experiment included parasites (5  104/ml inoculum) without drug treatment, and the trypanosome-free experiment did not
include parasites or drug treatment. Each curve represents the mean of three incubations.
FIG 5 Microcalorimetry growth profiles of T. b. gambiense strains STIB930 (A and C) and ITMAP141267 (B and D) in the presence of various concentrations
of DB829 (A and B) and pentamidine (C and D). The drug-free experiment included parasites (5  104/ml inoculum) without drug treatment and the
trypanosome-free experiment did not include parasites or drug treatment. Each curve represents the mean of three incubations.
Wenzler et al.
5338 aac.asm.org Antimicrobial Agents and Chemotherapy
 on A









aza-diamidines led to the further testing of DB829 in a second-
stage HAT monkey model (results will be published in due course)
and in the present study to the comprehensive pharmacological
characterization of DB829 and the comparator drug pentamidine
with two human-infective T. brucei subspecies. Effectiveness
against T. b. gambiense is of special interest since most HAT pa-
tients are infected with this trypanosome subspecies.
In comparison to the activity against the reference strain T.
b. rhodesiense STIB900, the potency of DB829 in vitro against T.
b. gambiense strains was reduced, ranging from 3.5- to 15-fold
FIG 6 Effects of drug washout on microcalorimetry growth profiles of T. b. rhodesiense strain STIB900 (A) and T. b. gambiense strain STIB930 (B) in the presence
of DB829. Drug washout was performed after a 24-h exposure to DB829. The drug-free experiment included parasites (5  104/ml inoculum) without drug
treatment. Each curve represents the mean of three incubations.
TABLE 5 Effects of inoculum and drug washout on drug action of DB829 and pentamidine by isothermal microcalorimetry















STIB900 0 (drug free) 37 (4) 123 (12) 28 (3)
5  104/ml DB829 20 22 (5) 34 (2) 98 (4) 22 (4) 15
200 10 (2) 24 (3) 72 (8) 13 (2) 52
Pentamidine 0.2 20 (1) 36 (4) 134 (11) 27 (2) 4
2 12 (2) 30 (2) 84 (14) 19 (5) 35
20b 3 (1) 9 (2) 21 (9) 1 98
1  104/ml 0 (drug free) 52 (5) 135 (13) 27 (1)
DB829 20 17 (4) 33 (2) 69 (7) 8 (3) 72
200b 14 (2) 16 (4) 36 (12) 2 (2) 90
Pentamidine 0.2a,c 20 (1) 42 (3) 152 (9) 28 (1) 3
2b 12 (3) 20 (4) 40 (5) 1 97
20b NMe NM NM 1 99
5  104/ml Washout 0 (drug free) 59 (5) 132 (5) 26 (2)
DB829 200c 27 46 (6) 96 (6) 9 (0.4) 64
STIB930 0 (drug free) 52 (2) 151 (9) 25 (2)
5  104/ml DB829 200 27 (6) 51 (1) 121 (4) 24 (1) 4
2,000c 16 (5) 39 (1) 89 (2) 12 (1) 52
Pentamidine 0.2d 4 53 (1) 163 (19) 23 (1) 8
2 6 (1) 29 (7) 66 (12) 8 (3) 67
1  104/ml 0 (drug free) 69 (2) 159 (11) 24 (2)
DB829 200 34 (10) 56 (4) 111 (10) 14 (3) 42
2,000b,c 15 (5) 37 (4) 66 (3) 2 (0.3) 91
Pentamidine 0.2d 6 74 (2) 161 (5) 22 (4) 12
2b 6 NM NM NM 100
5  104/ml Washout 0 (drug free) 63 (5) 154 (11) 21 (1)
DB829 200c 27 60 (2) 128 (9) 21 (0.5) 0
2,000d 27 58 (2) 130 (12) 15 (2) 28
a Inhibition was too small to accurately recover parameters from every experiment performed.
b Inhibition was too strong to accurately recover parameters from every experiment performed.
c Two independent experiments were performed (each in triplicate).
d One independent experiment was performed (in triplicate).
e NM, not measurable.
f Inhibition is measured by the formula [1  (drug/drugfree)]  100.
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(Table 3). Pentamidine also displayed a reduction in potency (2-
to 27-fold) against most T. b. gambiense strains, except for
STIB930 and DAL898R strains (Fig. 3). No cross-resistance be-
tween DB829 and pentamidine was observed in this study, which
included isolates from relapsed patients, in contrast to the cross-
resistance previously reported for pentamidine and melarsoprol
(39, 40). Transporters are known to be an important determinant
for developing resistance in trypanosomes to pentamidine and
melarsoprol (41–44). The P2 aminopurine transporter plays a
predominant role in the uptake of aza analogues of furamidine
into T. b. brucei s427 trypanosomes (45). The limited cross-resis-
tance of DB829 to pentamidine is presumably because different
transporters (41, 46)—in addition to P2—are involved in drug
uptake of both pentamidine and melarsoprol but do not transport
DB829. The existence of less efficient transporters in the T. b.
gambiense strains may also explain the observed lower in vitro
potency of DB829 against these parasite strains.
Despite being less active against T. b. gambiense strains in vitro,
DB829 was surprisingly more efficacious in vivo, curing all mice
infected with different T. b. gambiense isolates at all dose regimens
tested (Table 3). In particular, a single dose of DB829 adminis-
tered intraperitoneally was highly effective, curing all T. b. gam-
biense-infected animals at a dose as low as 5 mg/kg of body weight,
whereas the same dose of DB829 cured only 2/4 mice infected with
T. b. rhodesiense strain STIB900. The high efficacy of the lowest
DB829 doses used in our present study meant that the minimal
curative dose of DB829 for T. b. gambiense-infected mice has not
yet been established. In comparison, pentamidine was less effica-
cious than DB829 in T. b. gambiense-infected mice (3/4 cures at 5
mg/kg, single dose, compared with 4/4 or 3/3 cures with DB829)
and in T. b. rhodesiense-infected mice (1/4 cures compared to 4/4
cures at 4  5 mg/kg or 2/4 versus 4/4 cures at 20 mg/kg, single
dose, respectively).
Two factors may have contributed to the observed difference in
the activity of DB829 against T. b. gambiense in vitro and in vivo.
First, downregulation of diamidine uptake transporter(s) (e.g., P2
aminopurine transporter) under the in vitro culturing conditions
could have reduced the susceptibility of the T. b. gambiense isolates
to DB829, whereas in vivo bloodstream trypanosomes in infected
mice maintain a normal expression and function of diamidine
uptake transporter(s) and hence would be more susceptible to
DB829 than trypanosomes in in vitro culture. A striking decrease
(from 100% to 4.2%) in the functional activity of the P2 amino-
purine transporter in T. b. brucei s427 cells over a 24-h culture
period after fresh isolation from an infected rat was observed by
Ward et al. (45). However, it is yet to be demonstrated that such
downregulation of the P2 aminopurine transporter also occurred
in the T. b. gambiense isolates tested in vitro in our study. The
FIG 7 Inoculum effect on microcalorimetry growth profiles of T. b. rhodesiense strain STIB900 (A and C) and T. b. gambiense strain STIB930 (B and D) in the
presence of various concentrations of DB829 (A and B) and pentamidine (C and D). Two initial trypanosome densities were tested: standard inoculum at 5 
104/ml and low inoculum at 1  104/ml. The drug-free experiment included parasites without drug treatment, and the trypanosome-free experiment did not
include parasites or drug treatment. Each curve represents the mean of three incubations.
TABLE 6 In vivo time to kill (parasite clearance time) in infected mice
administered DB829 or pentamidinea
T. brucei strains
Mean (range) time to kill (h)
DB829 Pentamidine
STIB900 78 (72–80) 26 (24–32)
ITMAP141267 102 (96–120) 30 (24–48)
STIB930 62 (56–80) 48 (48)
a Mean data for four mice per group; range, time elapsed between the first mouse and
the last mouse becoming aparasitemic. For each drug, a single dose of 20 mg/kg was
administered i.p. on day 3 postinfection.
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observed decrease in in vitro potency (IC50) of the T. b. gambiense
isolates did not seem to have a major effect on the time to kill. At
approximately 10 IC50 the in vitro and in vivo times to kill were
similar (Tables 4 and 6), which indicates that the drug uptake in
vitro was high enough to kill the parasites in a period similar to
that in vivo.
A second reason for the greater potency of DB829 against T. b.
gambiense isolates in vivo compared with T. b. rhodesiense could
have been the levels of parasitemia. Mice infected with T. b. gam-
biense strains generally have a lower parasitemia (107 trypano-
somes/ml of blood) than those infected with T. b. rhodesiense
strain STIB900 (108 trypanosomes/ml of blood) (47). An inoc-
ulum effect (i.e., initial parasite density-dependent growth inhibi-
tion) could result in a better-than-expected in vivo activity due to
lower parasitemia in mice infected with T. b. gambiense strains.
We assessed inoculum effects on time of drug action by DB829
and pentamidine in vitro using isothermal microcalorimetry and
confirmed that inhibition of trypanosome growth rate by DB829
and pentamidine depended on the initial inoculum: the lower the
density of parasites, the stronger the inhibition of growth of either
T. b. rhodesiense or gambiense strains (Fig. 7 and Table 5). Al-
though the causes of the inoculum effect are still unclear to us
(see additional discussion in the supplemental material), the
observed inoculum effect is not expected to have any untoward
effect on efficacy in HAT patients treated with pentamidine (or
potentially DB829), since parasitemia in human patients, espe-
cially those with T. b. gambiense infections, is very low (105
trypanosomes/ml).
Using isothermal microcalorimetry, we were able to make a
real-time comparison of the effects of different drugs on different
parasite strains. It provided us with a convenient tool to monitor
parasite growth and to visualize and quantify the level of growth
rate inhibition by antiparasitic drugs on a real-time basis. Wenzler
et al. (19) first described the use of this technology to characterize
the parasite growth and effects of drug treatments for T. brucei and
Plasmodium falciparum. Here we used mathematical models and
included an additional parameter, growth rate (). The new four-
parameter model (onset of drug action, time to peak, time to kill,
and growth rate) describes time of drug action in more detail.
The inoculum effect was revealed by using the same drug con-
centration but different initial inocula (Table 5). The effect on the
inhibition of growth rate is discussed above. In contrast, inoculum
effects were not as clearly apparent on onset of drug action or time
to peak. This indicates that the drug action starts almost simulta-
neously at identical drug concentrations for DB829 and pentam-
idine at the different inocula. Inhibition is considerably stronger
in the samples with lower trypanosome densities, when their
drug-free control samples are still in the exponential growth
phase. On the other hand, at higher parasite densities inhibition
may be less observable because the onset of drug action and/or
time to peak is already close to the stationary phase, when growth
of the drug-free control samples is reduced as well—not by drug
inhibition but due to overgrowth of the parasite culture. Growth
inhibition by slow-acting drugs was less visible at higher inocula
since a decreased metabolic activity may coincide with the over-
growing culture.
The time of onset of drug action is a pharmacodynamic param-
eter that is important when considering potential use for treat-
ment. A main feature of isothermal microcalorimetry is real-time
monitoring of organism growth, which can be used to readily
calculate in vitro time of drug action. Traditionally, time of drug
action was obtained through laborious multiple single time point
antiparasitic inhibition assays with variable drug exposure times.
Onset of action, time to peak, and time to kill could only be esti-
mated, and the level of inhibition was calculated at the few tested
time points (19). Microcalorimetry offers a more reliable and less
laborious method. However, as the microcalorimeter typically re-
quires a few hours to fully equilibrate 4-ml ampoules containing 2
ml of culture medium, the analysis of onset of drug action is still
difficult, especially for fast-acting compounds. Further technical
improvements (e.g., adding an injection system) will be desirable
to allow preequilibration of ampoules prior to injecting com-
pound solutions, thus reducing the equilibration time following
drug addition (48).
DB829 was shown to be a slow-acting trypanocidal compound.
It was possible to obtain reliable results for the in vitro time to kill
at a range of concentrations. This ranged from 3 to 4 days for T. b.
rhodesiense strain STIB900 and from 4 to 5 days for the T. b. gam-
biense strains, depending on effective (0.5 IC50) drug concen-
trations (Table 4). In comparison, pentamidine is faster acting,
reducing parasites to below the detection limit within 1 day after
drug addition at 200 nM concentration for all three strains and at
20 nM for STIB900 and ITMAP141267. This is probably due to
differences in the parasite uptake kinetics of the two compounds,
which have been previously characterized using T. b. brucei strain
s427 (45, 49). It is noteworthy that parasites of T. b. rhodesiense
strain STIB900 grew faster than those of the two T. b. gambiense
strains in the absence of drug treatment, resulting in a shorter time
to death of the parasite culture (approximately 5 days versus 6 to 7
days, respectively) as a result of overgrowing. Since our standard
in vitro growth inhibition assays utilize a 72-h of incubation pe-
riod, we believe that the slow trypanocidal action of DB829 con-
tributed, in part, to the increases in measured IC50s against the T.
b. gambiense strains.
Activity of DB829 in vitro was not increased with drug concen-
trations higher than 2,000 nM (Fig. 4A and 5A and B). This is most
likely due to the saturation of the P2 transporter, which is the main
route of DB829 uptake (45). In a P2 transporter-mediated uptake
assay, the Michaelis-Menten constant, Km, of DB829 is 1.1 M,
indicating that saturation (maximum uptake rate, Vmax) is almost
reached after 2 M and therefore no significant higher inhibition
can be expected with this compound at higher drug concentra-
tions.
Parasite clearance time in vivo, following a single intraperito-
neal injection of DB829 at a dose of 20 mg/kg of body weight,
ranged from 3 to 3.3 days for mice infected with T. b. rhodesiense
strain STIB900 and from 2.3 to 5 days for mice infected with the
different T. b. gambiense strains (Table 6). These times were in
good agreement with the in vitro times to kill, given the high con-
centration in plasma of DB829 (Cmax  31.6 M) reached at this
dose level (Table 2). As predicted based on in vitro time to kill,
pentamidine is also faster acting in vivo than DB829, clearing par-
asites from the bloodstream within 1 to 1.3 days for mice infected
with T. b. rhodesiense strain STIB900 and 1 to 2 days for mice
infected with the T. b. gambiense strains. In summary, it generally
takes more time for DB829 to clear T. brucei parasites than for
pentamidine.
An interesting feature of the action of DB829 is that despite
being slow acting, it was able to kill parasites in vitro after a short
(24-h) drug exposure, as demonstrated by drug washout experi-
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ments (Fig. 6 and Table 5). This is consistent with the observation
that a single dose of DB829 could effectively cure infected mice
(Table 3), which was partially due to desirable pharmacokinetics,
with a high maximum drug concentration in plasma, relatively
long terminal elimination half-life at the dose tested, and relatively
low plasma protein binding (Table 2).
Based on the outstanding efficacy of DB829 in the mouse mod-
els with acute infections and its desirable pharmacokinetic prop-
erties, it is of interest to consider the potential value of this com-
pound in the treatment of HAT. A single dose of DB829
administered intramuscularly could be suggested as a new short
treatment for first-stage HAT. An even more important property
of DB829 is that it was shown to be efficacious in mice with sec-
ond-stage infection when administered intraperitoneally (10).
This has prompted further testing of parenteral DB829 (as well as
its methamidoxime oral prodrug, DB868) in the vervet monkey
model for second-stage HAT with promising results (16).
New, safe, and effective drugs are urgently needed for treat-
ment of both stages of HAT. It is also desirable that they be easy to
administer, with a simple dosing regimen. With improved drugs,
it should be possible to control HAT effectively and perhaps even
eliminate the disease. DB829 is a promising candidate for further
development. It is CNS active (by itself, without bioconversion),
so it could be used against second-stage HAT. In mouse models, it
showed outstanding efficacy against both first and second stages of
infection. Furthermore, it cured both T. b. gambiense and T. b.
rhodesiense infections at low and well-tolerated doses. Parenteral
DB829 with a short dosing regimen such as 5 days or less for the
second stage and a single dose for the first stage should be seriously
considered for further development as a new treatment for sleep-
ing sickness.
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